Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: An analysis of 63 cases

Tsai Shen Yang, Hsien Khun Chang, Jen Shi Chen, Yung Chang Lin, Chi Ting Liau, Wen Chang Chang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background. We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival. Methods. Sixty-three patients suffering from unresectable and non-embolizable HCC and who had objectively measurable tumors, adequate liver and renal function, and adequate bone-marrow reserve were enrolled in this study. The therapeutic regimen consisted of cisplatin 80mg/m2 and mitoxantrone 6mg/m2 intravenously on day 1, and 5-FU 450mg/m2 per day continuous infusion for a period of 5 days. Univariate and multivariate analyses of patient and disease characteristics were used to identify factors predicting patient response and survival. Results. The objective response was 23.8% (95% confidence interval [CI], 13.0-34.6%). The median survival for all 63 patients was 4.9 months (95% CI, 3.2-6.6 months). The median time to progression was 2.5 months (95% CI, 1.7-3.3 months). Multi-variate analysis identified only performance status (P = 0.050) and liver tumor size (P = 0.012) as being significantly related to patient objective response. Independent variables associated with a better patient survival included: the absence of ascites (P = 0.003), a lower total bilirubin level (P = 0.026), and the patient being a positive chemotherapy responder (P = 0.009). Conclusions. The response rate to an FMP regimen was still unsatisfactory, although a specific subgroup of patients (good performance status, smaller liver tumor mass, good liver reserve, and distant metastasis) may benefit from this regimen.

Original languageEnglish
Pages (from-to)362-369
Number of pages8
JournalJournal of Gastroenterology
Volume39
Issue number4
DOIs
Publication statusPublished - Apr 1 2004
Externally publishedYes

Fingerprint

Mitoxantrone
Fluorouracil
Cisplatin
Hepatocellular Carcinoma
Drug Therapy
Survival
Liver
Confidence Intervals
Neoplasms
Bilirubin
Ascites
Multivariate Analysis
Bone Marrow
Neoplasm Metastasis
Kidney

Keywords

  • 5-fluorouracil
  • Cisplatin
  • Hepatocellular carcinoma
  • Mitoxantrone
  • Prognostic factors

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma : An analysis of 63 cases. / Yang, Tsai Shen; Chang, Hsien Khun; Chen, Jen Shi; Lin, Yung Chang; Liau, Chi Ting; Chang, Wen Chang.

In: Journal of Gastroenterology, Vol. 39, No. 4, 01.04.2004, p. 362-369.

Research output: Contribution to journalArticle

Yang, Tsai Shen ; Chang, Hsien Khun ; Chen, Jen Shi ; Lin, Yung Chang ; Liau, Chi Ting ; Chang, Wen Chang. / Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma : An analysis of 63 cases. In: Journal of Gastroenterology. 2004 ; Vol. 39, No. 4. pp. 362-369.
@article{44e9ad8ccc2844d3b7615d4c65dcbb3c,
title = "Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: An analysis of 63 cases",
abstract = "Background. We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival. Methods. Sixty-three patients suffering from unresectable and non-embolizable HCC and who had objectively measurable tumors, adequate liver and renal function, and adequate bone-marrow reserve were enrolled in this study. The therapeutic regimen consisted of cisplatin 80mg/m2 and mitoxantrone 6mg/m2 intravenously on day 1, and 5-FU 450mg/m2 per day continuous infusion for a period of 5 days. Univariate and multivariate analyses of patient and disease characteristics were used to identify factors predicting patient response and survival. Results. The objective response was 23.8{\%} (95{\%} confidence interval [CI], 13.0-34.6{\%}). The median survival for all 63 patients was 4.9 months (95{\%} CI, 3.2-6.6 months). The median time to progression was 2.5 months (95{\%} CI, 1.7-3.3 months). Multi-variate analysis identified only performance status (P = 0.050) and liver tumor size (P = 0.012) as being significantly related to patient objective response. Independent variables associated with a better patient survival included: the absence of ascites (P = 0.003), a lower total bilirubin level (P = 0.026), and the patient being a positive chemotherapy responder (P = 0.009). Conclusions. The response rate to an FMP regimen was still unsatisfactory, although a specific subgroup of patients (good performance status, smaller liver tumor mass, good liver reserve, and distant metastasis) may benefit from this regimen.",
keywords = "5-fluorouracil, Cisplatin, Hepatocellular carcinoma, Mitoxantrone, Prognostic factors",
author = "Yang, {Tsai Shen} and Chang, {Hsien Khun} and Chen, {Jen Shi} and Lin, {Yung Chang} and Liau, {Chi Ting} and Chang, {Wen Chang}",
year = "2004",
month = "4",
day = "1",
doi = "10.1007/s00535-003-1303-8",
language = "English",
volume = "39",
pages = "362--369",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma

T2 - An analysis of 63 cases

AU - Yang, Tsai Shen

AU - Chang, Hsien Khun

AU - Chen, Jen Shi

AU - Lin, Yung Chang

AU - Liau, Chi Ting

AU - Chang, Wen Chang

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Background. We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival. Methods. Sixty-three patients suffering from unresectable and non-embolizable HCC and who had objectively measurable tumors, adequate liver and renal function, and adequate bone-marrow reserve were enrolled in this study. The therapeutic regimen consisted of cisplatin 80mg/m2 and mitoxantrone 6mg/m2 intravenously on day 1, and 5-FU 450mg/m2 per day continuous infusion for a period of 5 days. Univariate and multivariate analyses of patient and disease characteristics were used to identify factors predicting patient response and survival. Results. The objective response was 23.8% (95% confidence interval [CI], 13.0-34.6%). The median survival for all 63 patients was 4.9 months (95% CI, 3.2-6.6 months). The median time to progression was 2.5 months (95% CI, 1.7-3.3 months). Multi-variate analysis identified only performance status (P = 0.050) and liver tumor size (P = 0.012) as being significantly related to patient objective response. Independent variables associated with a better patient survival included: the absence of ascites (P = 0.003), a lower total bilirubin level (P = 0.026), and the patient being a positive chemotherapy responder (P = 0.009). Conclusions. The response rate to an FMP regimen was still unsatisfactory, although a specific subgroup of patients (good performance status, smaller liver tumor mass, good liver reserve, and distant metastasis) may benefit from this regimen.

AB - Background. We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival. Methods. Sixty-three patients suffering from unresectable and non-embolizable HCC and who had objectively measurable tumors, adequate liver and renal function, and adequate bone-marrow reserve were enrolled in this study. The therapeutic regimen consisted of cisplatin 80mg/m2 and mitoxantrone 6mg/m2 intravenously on day 1, and 5-FU 450mg/m2 per day continuous infusion for a period of 5 days. Univariate and multivariate analyses of patient and disease characteristics were used to identify factors predicting patient response and survival. Results. The objective response was 23.8% (95% confidence interval [CI], 13.0-34.6%). The median survival for all 63 patients was 4.9 months (95% CI, 3.2-6.6 months). The median time to progression was 2.5 months (95% CI, 1.7-3.3 months). Multi-variate analysis identified only performance status (P = 0.050) and liver tumor size (P = 0.012) as being significantly related to patient objective response. Independent variables associated with a better patient survival included: the absence of ascites (P = 0.003), a lower total bilirubin level (P = 0.026), and the patient being a positive chemotherapy responder (P = 0.009). Conclusions. The response rate to an FMP regimen was still unsatisfactory, although a specific subgroup of patients (good performance status, smaller liver tumor mass, good liver reserve, and distant metastasis) may benefit from this regimen.

KW - 5-fluorouracil

KW - Cisplatin

KW - Hepatocellular carcinoma

KW - Mitoxantrone

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=2542430373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542430373&partnerID=8YFLogxK

U2 - 10.1007/s00535-003-1303-8

DO - 10.1007/s00535-003-1303-8

M3 - Article

C2 - 15168248

AN - SCOPUS:2542430373

VL - 39

SP - 362

EP - 369

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 4

ER -